![]() ![]() ![]() When diseased cells are present, the immune system is activated through the intricate and complex biological process known as the immune synapse – the interaction between specific T cells and the corresponding antigen-presenting cells that dictate T cell activity. ![]() Repertoire Immune Medicines is a clinical-stage biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function. Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates. In particular, the platform identifies T cell receptor-antigen pairs in the context of other important features of the immune synapse, such as T cell function and how these antigens are presented by molecules on antigen-presenting cells, known as major human leukocyte antigen, or HLA, molecules. The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse. Poster #177: Understanding the T cell Repertoire in Autoimmune Diseases Using High-Dimensional Single-Cell Analysis of Antigen-Specific CD4+ and CD8+ T cells Session: Mechanisms of Immune Dysregulation, 3:00 – 5:00 p.m. Oral Presentation: Understanding the T cell Repertoire in Autoimmune Diseases Using High-Dimensional Single-Cell Analysis of Antigen-Specific CD4+ and CD8+ T cells This research is detailed in the DECODE data presentations at FOCIS 2022: Repertoire is investigating optimal modalities to deliver immune medicines that target the identified epitopes and potentially treat T1D. By identifying these epitopes, it may be possible to develop new antigen-specific treatments that stop the immune system from damaging healthy cells and change the course of T1D. T cells respond to the immunodominant epitopes present in these antigens. While it is not fully understood why this occurs, it is known that T cells are activated by antigens that are inappropriately recognized by the immune system as foreign. In autoimmune diseases like T1D, T cells target and damage healthy cells. The novel targets we discovered are also present in recently diagnosed patients, suggesting these epitopes may be viable targets to treat patients early in the course of their disease before tissue damage becomes extensive." "Our DECODE platform allows us to identify the specificity of T cells that cause the dysregulated immune response underlying type 1 diabetes. "Immune-based medicines that target the mechanisms that underlie autoimmune diseases offer the potential to slow down or even halt disease progression," said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. ![]() The research was conducted with Repertoire’s DECODE™ platform and will be presented at the 22nd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2022). Proprietary DECODE™ platform used to identify previously unknown epitopes and T cell receptors in the peripheral blood and in pancreatic islets from early and advanced T1D patients, providing potential new targets for immune medicinesĬAMBRIDGE, Mass., June 23, 2022-( BUSINESS WIRE)- Repertoire Immune Medicines today announced its discovery of previously unidentified epitopes involved in the pathogenesis of type 1 diabetes (T1D). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |